Our mission is to provide the first non-pharmacological topical treatment. Our primary goal is to full the existing MARKET GAP in PEDIATRIC dermatology, focusing on atopic dermatitis.

To do so, we developed a medical device, called LimpiAD, using a biotechnology platform (HA c-40) involving non-pathogenic bacteria.

HA c-40

LimpiAD has proven to be safe, well-tolerated, and effective in topically treating mild to moderate seborrheic dermatitis (SD) and has been approved pediatric atopic dermatitis. Seeing the interaction of cutaneous microbiota in diseases such as acne and psoriasis, our next goal is to test LimpiAD on these diseases. HA c-40 treatments provide a competitive and valid alternative to currently invasive treatment approaches that are not well-accepted by all patients.

These features make LimpiAD a ground-breaking product in a market that has not seen innovation for many years.

HA c-40

LimpiAD has proven to be safe, well-tolerated, and effective in topically treating mild to moderate seborrheic dermatitis (SD) and has been approved pediatric atopic dermatitis. Seeing the interaction of cutaneous microbiota in diseases such as acne and psoriasis, our next goal is to test LimpiAD on these diseases. HA c-40 treatments provide a competitive and valid alternative to currently invasive treatment approaches that are not well-accepted by all patients.

These features make LimpiAD a ground-breaking product in a market that has not seen innovation for many years.

The HA c-40 project platform

The HA c-40 device involves the use of a non-pathogenic bacterial fragment (cellular wall), at times naturally present on human skin, which is then chemically conjugated with mucopolysaccharides acting as carriers. HA c-40 has been shown to be highly effective, in a prospective pilot open-label study, in reducing the signs and symptoms of oxazolone-induced dermatitis (13).

A first clinical trial that tested the use of LimpiAD on human subjects (60 children) confirmed the product’s effectiveness. Additional studies with higher numbers of subjects are being planned.

A proof-of-concept study showed the effectiveness of LimpiAD in reducing the signs and symptoms of seborrheic dermatitis on the face and chest. The use of HA c-40 5% significantly reduced IGA scores by 67% at week 3 and by 83% at week 6. HAS50 was effective in reducing eczema and was very well tolerated. No local side effects were reported (14).

The HA c-40 project platform

The HA c-40 device involves the use of a non-pathogenic bacterial fragment (cellular wall), at times naturally present on human skin, which is then chemically conjugated with mucopolysaccharides acting as carriers. HA c-40 has been shown to be highly effective, in a prospective pilot open-label study, in reducing the signs and symptoms of oxazolone-induced dermatitis (13).

A first clinical trial that tested the use of LimpiAD on human subjects (60 children) confirmed the product’s effectiveness. Additional studies with higher numbers of subjects are being planned.

A proof-of-concept study showed the effectiveness of LimpiAD in reducing the signs and symptoms of seborrheic dermatitis on the face and chest. The use of HA c-40 5% significantly reduced IGA scores by 67% at week 3 and by 83% at week 6. HAS50 was effective in reducing eczema and was very well tolerated. No local side effects were reported (14).

References

1. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121-41.
2. Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, et al. Topographical and temporal diversity of the human skin microbiome. Science. 2009;324(5931):1190-2.
3. Lee N, Kim WU. Microbiota in T-cell homeostasis and inflammatory diseases. Exp Mol Med. 2017;49(5):e340.
4. Gallo RL. Human skin is the largest epithelial surface for interaction with microbes. J Invest Dermatol. 2017;137:1213-1214.
5. Cogen AL, Nizet V, Gallo RL. Skin microbiota: a source of disease or defence?.Br J Dermatol. 2008; 158(3):442-55.
6. Teruaki Nakatsuji, Richard L. Gallo. The role of the skin microbiome in atopic dermatitis. Annals of Allergy, Asthma & Immunology 2018. https://doi.org/10.1016/j.anai.2018.12.003
7. Geoghegan JA, Irvine AD, Foster TJ. Staphylococcus aureus and Atopic Dermatitis: A Complex and Evolving Relationship. Trends Microbiol.2018;26(6):484-97.
8. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab.2015;66 Suppl 1:8-16.

9. Lifschitz C. The impact of atopic dermatitis on quality of life. Ann Nutr Metab.2015;66 Suppl 1:34-40.
10. Fernandez JM, Fernandez AP, Lang DM. Biologic Therapy in the Treatment of Chronic Skin Disorders. Immunol Allergy Clin North Am. 2017;37(2):315-27
11. Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: A long overdue revisit. Indian Dermatol Online J. 2014;5(4):416-25.
12. Li AW, Yin ES, Antaya RJ. Topical Corticosteroid Phobia in Atopic Dermatitis: A Systematic Review. JAMA Dermatol. 2017;153(10):1036-42.
13. Mangano K, Vergalito F, Mammana S, Mariano A, De Pasquale R, Meloscia A, et al.Evaluation of hyaluronic acid-P40 conjugated cream in a mouse model of dermatitis induced by oxazolone. Exp Ther Med. 2017;14(3):2439-44.
14. Journal of Clinical & Experimental Dermatology Research Milani et al., J Clin Exp Dermatol Res 2017, 8:6

DOI: 10.4172/2155-9554.1000426

1. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014;157(1):121-41.
2. Grice EA, Kong HH, Conlan S, Deming CB, Davis J, Young AC, et al. Topographical and temporal diversity of the human skin microbiome. Science. 2009;324(5931):1190-2.
3. Lee N, Kim WU. Microbiota in T-cell homeostasis and inflammatory diseases. Exp Mol Med. 2017;49(5):e340.
4. Gallo RL. Human skin is the largest epithelial surface for interaction with microbes. J Invest Dermatol. 2017;137:1213-1214.
5. Cogen AL, Nizet V, Gallo RL. Skin microbiota: a source of disease or defence?.Br J Dermatol. 2008; 158(3):442-55.
6. Teruaki Nakatsuji, Richard L. Gallo. The role of the skin microbiome in atopic dermatitis. Annals of Allergy, Asthma & Immunology 2018. https://doi.org/10.1016/j.anai.2018.12.003
7. Geoghegan JA, Irvine AD, Foster TJ. Staphylococcus aureus and Atopic Dermatitis: A Complex and Evolving Relationship. Trends Microbiol.2018;26(6):484-97.
8. Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab.2015;66 Suppl 1:8-16.
9. Lifschitz C. The impact of atopic dermatitis on quality of life. Ann Nutr Metab.2015;66 Suppl 1:34-40.
10. Fernandez JM, Fernandez AP, Lang DM. Biologic Therapy in the Treatment of Chronic Skin Disorders. Immunol Allergy Clin North Am. 2017;37(2):315-27
11. Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: A long overdue revisit. Indian Dermatol Online J. 2014;5(4):416-25.
12. Li AW, Yin ES, Antaya RJ. Topical Corticosteroid Phobia in Atopic Dermatitis: A Systematic Review. JAMA Dermatol. 2017;153(10):1036-42.
13. Mangano K, Vergalito F, Mammana S, Mariano A, De Pasquale R, Meloscia A, et al.Evaluation of hyaluronic acid-P40 conjugated cream in a mouse model of dermatitis induced by oxazolone. Exp Ther Med. 2017;14(3):2439-44.
14. Journal of Clinical & Experimental Dermatology Research Milani et al., J Clin Exp Dermatol Res 2017, 8:6

DOI: 10.4172/2155-9554.1000426